2016 Apr 7 – Issues facing biotech and specialist companies

Seminar 07 Apr Final 2

Changes in the way new medicines are being developed

The last decade has seen significant changes in the way new medicines are being developed and commercialized for the market. A combination of high cost, high risk and an unstable global economy has resulted in a resurgence of mergers, acquisitions and, in particular, commercial alliances between Big Pharma, Biotech and Specialist companies.

These types of alliance bring their own challenges and will be the focus of this Open Seminar.

Using, as examples, the recent deals with Janssen Biotech and Astellas, Eva Dahlén from Alligator Bioscience and Lena Mårtensson from Leo Pharma will describe what is involved in developing new ideas beyond the discovery and early-development phase as well as the importance to the business of establishing long-term commercial relationships.

In addition to providing a general description of the two companies, Lena and Eva will also describe some of the potential job opportunities available and the qualifications and experience needed.

Speaker Eva Dahlén

* Current position: Principal scientist and business intelligence at Alligator Bioscience

Dr. Dahlén is a Principal Scientist at Alligator Bioscience. She is project leader and scientifically responsible in various drug discovery and research programs in the field of immuno-oncology. In addition, she is responsible for business intelligence as well as for scientific business development, establishing and maintaining partnerships with academia and biotech companies in relevant areas. Dr. Dahlén holds a PhD in immunology from Lund University. She has been employed by Alligator Bioscience since 2004. Previous affiliations include Malmö university, Lund university and Active Biotech.

Speaker Lena Mårtensson

*  Current position: Senior Director and Head of Pipeline sourcing at LEO.

This position means that she leads the in licensing efforts from early stage in discovery up to Phase III in development, mainly for compounds, but it could also be technology platforms and strategic partnership with key academic centers.

Dr. Mårtensson is in the Board of Directors in Genovis, Oncorena and a senior partner and member of the Investment committee in Pulse. She also takes part in the MentLife program, being a mentor when needed, along with belonging to the Rotary club in Helsingborg.

Her background is PhD and Associate Professor of Physiology from University of Lund, with extensive fellowships done in the US and in the Netherlands. It was also in the Netherlands she did her postdoc at the Erasmus Medical School in Rotterdam.

Dr. Mårtensson has worked since then in the Life science industry for over 30 years, holding leadership positions at Gambro AB, Perstorp, Pharmacia/Pfizer and AstraZeneca.

Speaker Tomas Högberg

Tomas Högberg will set the scene for the presentations of Eva Dahlén and Lena Mårtensson.

Dr. Högberg has spent 45 years in the pharmaceutical industry and had leading roles from early drug discovery up to marketed products in various types of companies – Astra, AstraZeneca, ALK-Abelló, 7TM Pharma and presently LEO Pharma. Dr. Högberg has experience in drug design and development in several therapeutic areas including dermatology, obesity, diabetes, dyslipidaemia, inflammatory diseases, respiratory diseases, depression, psychosis, pain, and infection. He has a PhD in organic chemistry and became associate professor at KTH 1985. Dr. Högberg is a Fellow of the Royal Society of Chemistry (CChem, FRSC) since 1991 and he has published over 100 scientific papers and 50 patent applications.


Comments are closed.